Authors
Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, Efthymios N Deliargyris, Gregg W Stone, C Michael Gibson, Christian W Hamm, Kenneth W Mahaffey, Harvey D White, Dominick J Angiolillo, Jayne Prats, Robert A Harrington, Matthew J Price, CHAMPION Investigators*
Publication date
2018/4
Journal
Circulation: Cardiovascular Interventions
Volume
11
Issue
4
Pages
e005635
Publisher
Lippincott Williams & Wilkins
Description
Background
The influence of cangrelor on the incidence and outcomes of post-percutaneous coronary intervention (PCI) thrombocytopenia is not defined. We aimed to explore the incidence, predictors, and clinical impact of thrombocytopenia after PCI in cangrelor-treated patients.
Methods and Results
This was a pooled, patient-level analysis of the CHAMPION trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition), which compared cangrelor with clopidogrel for prevention of thrombotic complications during and after PCI. Acquired thrombocytopenia was defined as either a drop in platelet count to <100 000 after PCI or a drop of >50% between baseline and a follow-up. The main efficacy outcome was major adverse cardiac events. The primary safety outcome was noncoronary artery bypass grafting–related Global Utilization of Streptokinase and Tissue Plasminogen …
Scholar articles
EM Groves, DL Bhatt, PG Steg, EN Deliargyris… - Circulation: Cardiovascular Interventions, 2018